Charles Schwab Portfolio holdings
Charles Schwab Corporation, founded in 1971 by Charles R. Schwab and headquartered in Westlake, Texas, is a leading financial services firm that revolutionized retail investing by offering low-cost brokerage services. Initially disrupting the industry with discount commissions, it has grown into a powerhouse providing a wide array of services, including trading platforms, robo-advisors, retirement accounts, and banking products, managing hundreds of billions in client assets. Known for its user-friendly technology and customer-centric approach, Schwab caters to individual investors, financial advisors, and institutions, notably expanding through its 2020 acquisition of TD Ameritrade. With a mission to democratize investing, Charles Schwab remains a dominant force in the shift toward accessible, self-directed wealth management.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$2.16B |
| 2 |
Hershey
HSY
|
+$663M |
| 3 |
Lockheed Martin
LMT
|
+$622M |
| 4 |
Altria Group
MO
|
+$525M |
| 5 |
Pfizer
PFE
|
+$499M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$2.76B |
| 2 |
Merck
MRK
|
+$2.35B |
| 3 |
Automatic Data Processing
ADP
|
+$1.57B |
| 4 |
Blackstone
BX
|
+$1.38B |
| 5 |
Illinois Tool Works
ITW
|
+$1.13B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.85% |
| 2 | Financials | 12.71% |
| 3 | Healthcare | 11.72% |
| 4 | Consumer Discretionary | 10.09% |
| 5 | Industrials | 9.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CTO
2801
CTO Realty Growth
CTO
$827M
| $983K | ﹤0.01% |
57,985
-1,709
| -3% | -$28.7K |
|
2802
Willdan Group
WLDN
$1.11B
| $982K | ﹤0.01% |
33,889
| – | – |
|
2803
Oil-Dri
ODC
$1.41B
| $982K | ﹤0.01% |
26,336
| – | – |
|
2804
Genelux
GNLX
$134M
| $981K | ﹤0.01% |
152,509
+2,905
| +2% | +$26.4K |
|
2805
Celcuity
CELC
$4.28B
| $979K | ﹤0.01% |
45,313
+36
| +0.1% | +$575 |
|
2806
Capital City Bank Group
CCBG
$898M
| $975K | ﹤0.01% |
35,215
-1,054
| -3% | -$29.6K |
|
2807
Harvard Bioscience
HBIO
$28.5M
| $974K | ﹤0.01% |
22,978
-690
| -3% | -$31K |
|
|
INZY
2808
DELISTED
Inozyme Pharma
INZY
| $969K | ﹤0.01% |
126,535
+4,885
| +4% | +$26.8K |
|
2809
Nkarta
NKTX
$154M
| $967K | ﹤0.01% |
89,428
+20,319
| +29% | +$211K |
|
2810
Bioventus
BVS
$913M
| $965K | ﹤0.01% |
185,651
+5,105
| +3% | +$24.9K |
|
2811
Boston Omaha
BOC
$437M
| $957K | ﹤0.01% |
61,884
-1
| -0% | -$16 |
|
2812
Orchestra BioMed
OBIO
$247M
| $947K | ﹤0.01% |
179,710
+4,165
| +2% | +$28.2K |
|
2813
Getty Images
GETY
$174M
| $946K | ﹤0.01% |
228,011
-8,897
| -4% | -$41.2K |
|
2814
UroGen Pharma
URGN
$1.88B
| $943K | ﹤0.01% |
62,880
| – | – |
|
2815
Artesian Resources
ARTNA
$352M
| $941K | ﹤0.01% |
25,345
-803
| -3% | -$29.3K |
|
|
KALV
2816
DELISTED
KalVista Pharmaceuticals
KALV
| $927K | ﹤0.01% |
78,138
-2,313
| -3% | -$30.8K |
|
2817
NWPX Infrastructure Inc
NWPX
$1.23B
| $923K | ﹤0.01% |
26,608
-55
| -0.2% | -$1.69K |
|
|
TAST
2818
DELISTED
Carrols Restaurant Group, Inc.
TAST
| $918K | ﹤0.01% |
96,483
-5,329
| -5% | -$49.2K |
|
|
JBIO
2819
Jade Biosciences
JBIO
$1.17B
| $915K | ﹤0.01% |
885
+41
| +5% | +$31.3K |
|
2820
Sutro Biopharma
STRO
$416M
| $909K | ﹤0.01% |
16,088
| – | – |
|
2821
Vanguard Materials ETF
VAW
$2.99B
| $908K | ﹤0.01% |
4,443
-1,299
| -23% | -$247K |
|
|
TEF
2822
DELISTED
Telefonica
TEF
| $906K | ﹤0.01% |
205,524
+70,926
| +53% | +$291K |
|
2823
Woodside Energy
WDS
$43.1B
| $904K | ﹤0.01% |
45,246
+18,152
| +67% | +$367K |
|
2824
Limoneira
LMNR
$239M
| $900K | ﹤0.01% |
46,016
-1,527
| -3% | -$28.4K |
|
2825
Esquire Financial Holdings
ESQ
$1.12B
| $900K | ﹤0.01% |
18,954
| – | – |
|
Similar funds
Charles Schwab's Q1 2024 Portfolio in Review
As of Q1 2024, Charles Schwab held 3,573 positions worth $433B, up 10% from $394B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Trading was light in Q1 2024: portfolio turnover was 3.8%. Charles Schwab opened 35 new positions and exited 102, leaving the 3,573-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 23% a quarter earlier, followed by Financials and Healthcare.
- Charles Schwab's largest Q1 2024 buy was Schwab Fundamental US Large Company Index ETF: 3,608,604 shares worth $81.1M.
- Charles Schwab added most to Bristol-Myers Squibb in Q1 2024, an estimated $2.16B increase.
- Charles Schwab's biggest Q1 2024 reduction was Broadcom, cutting an estimated $2.76B.
- Charles Schwab fully exited Splunk Inc in Q1 2024, selling an estimated $104M.
- Charles Schwab's ten largest holdings make up 20% of its $433B portfolio in Q1 2024.
- Charles Schwab opened 35 new positions and closed 102 in Q1 2024.
- Charles Schwab's portfolio value rose 10% quarter-over-quarter to $433B.
Based on Charles Schwab's 13F filing for Q1 2024, filed 9 May 2024.